Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases.
Our core technology is derived from a plant virus, cowpea mosaic virus ("CPMV") which is non-infectious to humans or other animals but upon intra-tumoral administration is recognized by immune cells as foreign, eliciting a strong local innate immune response through the activation of multiple toll-like receptors (TLRs). This TLR activation results in potent anti-tumor activity against the primary and distant tumor sites.
In oncology indications, our lead candidate, MIE-101, has demonstrated broad and consistent anti-tumor activity as a single agent in multiple preclinical tumor models and has demonstrated synergistic effects when combined with standard of care treatments. The research investigating this first-in-class intratumoral multi-TLR agonist continues to be supported by numerous publications and grant funding through our university collaborators.
Our technology is also being investigated as part of a modular vaccine platform, utilizing CPMV as an immune stimulant linked with viral or cancer antigens. Data generated to date show promising results in both cancer and infectious disease preclinical vaccine models, including COVID-19. The vaccine research is currently being performed by one of our co-founders and is funded by the National Science Foundation (NSF).
We are actively moving our unique technology platforms forward with the goal of filing an investigational new drug (IND) or similar application with the appropriate regulatory authorities to initiate clinical development of our lead candidates.
Experienced Founders and Management Team
Mosaic's founding members comprise a group with extensive scientific, business development and financial skills to move the company and its technology forward.
Our team's years of experience in the biotech industry have provided a strong foundation for Mosaic's rapid maturity to a publicly traded company with cutting edge technology and solid plans for continued development and growth.
Technology and company timeline